The prevalence of diabetes mellitus is progressively on the rise in India. It is considered
as equivalent to cardio vascular and cerebro vascular disease[1]. Treatment with allopathic
medicine though effective poses high economic burden on the individual and the well-known
side effects which reduces compliance[2]. There is constant search for drugs from
alternative medicine[3]. The PURSE HIS (Prevalence of risk factors and the detection
of occult and overt endovascular disease in Urban, Rural and SEmiurban regions with
Holistic Intervention Study) cohort study is an ongoing study addressing the above
issues. We provide intervention with Siddha medical system[4], according to willingness
of participants with abnormal plasma glucose level and serum lipid level conducting
a longitudinal follow up for three years. Participants above 20 years of age are provided
Madhumega Chooranam (MMC) (2X500mg capsules twice a day) to those with fasting plasma
glucose level 6.10–8.26 mmol/L and two hours plasma glucose level 11.1–16.59 mmol/L,
total cholesterol 4.53–5.69 mmol/L, triglyceride 1.69–2.83mmol/L and low density lipoprotein
2.07–3.10mmol/L. Base values are kept at a lower range as the compound is being tried
for the first time for the two risk factors according to the norms of good clinical
practice. Investigations were carried out during follow up visits for glycemic control,
lipid profile, renal and liver function tests and hematological parameters. Preliminary
phytochemical analysis and HPTLC finger printing were done. This pilot study reveals
that MMC has statistically significant hypoglycemic and hypolipidemic action with
no adverse effects.
|
Values are expressed in Mean±SD; N denotes number of subjects; P value denotes Statistical
significance compared to 0th day visit;
** *, ** & * denotes p values <0.001; <0.01; <0.05 respectively
|
|
Sl.No
|
Variables
|
N
|
Initial visit (mmol/L)
|
At 20 weeks (mmol/L)
|
Mean reduction(mmol/L)
|
P value
|
|
1
|
FBS
|
47
|
7.77±2.28
|
6.97±1.59*
|
0.80
|
0.032
|
|
2
|
PPBS
|
47
|
13.43±3.50
|
10.64±3.19***
|
2.79
|
0.000
|
|
3
|
HbA1c
|
47
|
7.67±1.20
|
7.19±0.99*
|
-
|
0.05
|
|
4
|
Total cholesterol
|
47
|
5.08±0.97
|
4.50±0.75***
|
0.58
|
0.000
|
|
5
|
Triglyceride
|
47
|
1.86±0.85
|
1.43±0.65***
|
0.43
|
0.000
|
|
6
|
LDL-cholesterol
|
47
|
3.32±0.89
|
3.00±0.66**
|
0.32
|
0.006
|
|
7
|
HDL-cholesterol
|
47
|
1.09±0.19
|
1.07±0.20
|
0.02
|
0.45
|
|
8
|
Non-HDL-cholesterol
|
47
|
3.99±0.93
|
3.42±0.68***
|
0.56
|
0.000
|
Acknowledgements: Thanks to Drugs and Pharmaceutical Research Program implemented by Technology development
and transfer division of Department of Science and Technology, Government of India,
New Delhi.
References:[1] Gupta OP, Phatak S (2003) Int J Diab Dev Countries 23(2): 37–50. [2] Grover S,
et al. (2005) Postgrad Med J 81: 391–395. [3] Dubey NK, Kumar R, et al. (2004) Cur
Sci, 86(1): 37–41. [4] Subbarayappa BV (1997) Lancet, 350(9094): 1841–4.
